TargetBeta
IL33
interleukin 33 · also DVS27, DKFZp586H0523, NF-HEV, IL1F11 · Interleukins
5 programs in company-led studies act on IL33, from 5 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| itepekimabrule | Sanofi | phase 3 | 173 running | – | ChEMBL |
| GSK3862995B | GlaxoSmithKline | phase 2 | 54 running | – | the company's pipeline |
| ompekimig | Pfizer | phase 2 | 31 running | IL13, IL4 | the company's pipeline |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 11 running | TSLP | the studies' text |
| HY6725rule | Newsoara Biopharma | phase 1 | 11 running | TSLP | the studies' text |
Conditions their studies are in
- Asthma, 2 programs
- Bronchiectasis, 2 programs
- Dermatitis, Atopic, 2 programs
- Pulmonary Disease, Chronic Obstructive, 2 programs
- Nasal Polyps, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 16, 2026GSK3862995B · GlaxoSmithKline · phase 2 · NCT06154837
- Feb 17, 2027itepekimab · Sanofi · phase 3 · NCT07424144
- Mar 2027HY6725 · Newsoara Biopharma · phase 1 · NCT07262281
- Feb 15, 2028HXN-1013 · Helixon Biotechnology (Suzhou) · phase 1 · NCT07900568
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.